Tonix Pharmaceuticals Holding Corp. (TNXP)

Trade TNXP now with
1/24/2020 7:04:08 AM Tonix Pharma Completes Fed-Fasting And Dose Proportionality Study Of TNX-102 SL
12/10/2019 7:10:00 AM Tonix Pharmaceuticals Says First Patient Enrolled In Phase 3 RELIEF Study
11/15/2019 8:33:49 AM Tonix Pharma Prices $9.0 Mln Public Offering
11/4/2019 7:14:33 AM Tonix Pharma Announces 12-Week Primary Endpoint In Currently-Enrolling Phase 3 RECOVERY Study Of Tonmya
9/16/2019 7:22:27 AM Tonix Announces Publication Of Paper On Triple Reuptake Inhibitor TNX-1600
9/4/2019 7:08:13 AM Tonix Pharma Doses Participants In Phase 1 Study Of TNX-601 For Daytime Treatment Of Posttraumatic Stress Disorder
7/16/2019 8:34:22 AM Tonix Pharma Announces Pricing Of Public Offering Of 9 Mln Shares At $0.60/Shr
6/13/2019 7:17:32 AM Tonix Reports Issuance Of Patent In China For Composition Of TNX-102 SL
4/22/2019 7:11:11 AM Tonix Pharma Says That Breakthrough Therapy Designation Remains In Effect For Tonmya For Posttraumatic Stress Disorder
3/11/2019 7:31:16 AM Tonix Pharma Enrolls First Participant In RECOVERY Study, A New Phase 3 Trial Of Tonmyafor Posttraumatic Stress Disorder
12/11/2018 4:08:33 PM Tonix Pharmaceuticals Closes $15 Mln Public Offering
12/7/2018 11:07:02 AM Tonix Pharmaceuticals Prices $15 Mln Public Offering
11/29/2018 7:04:04 AM Tonix Pharma Announces Additional Details Of New Phase 3 Study Of Tonmya For PTSD